We provide you with 20 years of free, institutional-grade data for GLYC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GLYC. Explore the full financial landscape of GLYC stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about GLYC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
GlycoMimetics, Inc(NASDAQ:GLYC) 
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment ...
Website: http://www.glycomimetics.com
Founded: 2003
Full Time Employees: 57
Founder: Rachel K. King
Sector: Healthcare
Industry: Biotechnology